DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Report
January 2, 2015
Systemic Lupus Eryhtematosus (What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe?) | Physician & Payer Forum | EU5 | 2014
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
Report
December 19, 2014
Squamous Cell Carcinoma of the Head and Neck | Niche and Rare Pharmacor | G7 | 2014
Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…
Report
December 19, 2014
Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 1 | 2014
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…
